Systematic information to health-care professionals about vaccination guidelines improves adherence in patients with inflammatory bowel disease in Anti-TNFα therapy

American Journal of Gastroenterology

Volumn 110, Issue 11, 2015, Pages 1526-1532

  Christensen, Katrine R ^a   Steenholdt, Casper ^a   Buhl, Sine S ^a   Ainsworth, Mark A ^a   Thomsen, Ole Ø ^a   Brynskov, Jørn ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VEDOLIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONSULTATION; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MIDDLE AGED; PATIENT COMPLIANCE; PERCEPTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; VACCINATION; ANTAGONISTS AND INHIBITORS; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; DENMARK; ECONOMICS; GASTROENTEROLOGY; INFLAMMATORY BOWEL DISEASES; INFORMATION DISSEMINATION; MEMORY; STANDARDS; STATISTICS AND NUMERICAL DATA; TIME;

ADULT; CROSS-SECTIONAL STUDIES; DENMARK; FEMALE; GASTROENTEROLOGY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFORMATION DISSEMINATION; MALE; MEMORY; MIDDLE AGED; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84949102156     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.162     Document Type: Article

References (18)

1. Nielsen OH, Ainsworth M.A. Tumor necrosis factor inhibitors for infl ammatory bowel disease. N Engl J Med 2013; 369: 754-62
2. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infl iximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 : 1098-104
3. Esteve M, Saro C, Gonzalez-Huix F et al. Chronic hepatitis B reactivation following infl iximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5
4. Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in infl ammatory bowel disease. J Crohns Colitis 2014; 8: 443-68
5. Siegel CA, Allen JI, Melmed GY. Translating improved quality of care into an improved quality of life for patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 908-12
6. http://www.gastro.org/practice/quality-initiatives/IBD-Measures.pdf October 2014
7. Feuerstein JD, Lewandowski JJ, Martinez-Vazquez M et al. Documented compliance with infl ammatory bowel disease quality measures is poor. Dig Dis Sci 2014; 60: 339-44
8. Vaughn BP, Doherty GA, Gautam S et al. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Infl amm Bowel Dis 2012; 18: 1057-63
9. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in infl ammatory bowel disease. J Crohns Colitis 2009; 3: 47-91
10. http://patientoplevelser.dk/sites/patientoplevelser.dk/files/dokumenter/ artikel/spoergeskema.pdf March 2013
11. Wilckens V, Kannengiesser K, Hoxhold K et al. The immunization status of patients with IBD is alarmingly poor before the introduction of specifi c guidelines. Scand J Gastroenterol 2011; 46: 855-61
12. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with infl ammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-40
13. Walsh AJ, Weltman M, Burger D et al. Implementing guidelines on the prevention of opportunistic infections in infl ammatory bowel disease. J Crohns Colitis 2013; 7: 449-56
14. Wasan SK, Calderwood AH, Long MD et al. Immunization rates and vaccine beliefs among patients with infl ammatory bowel disease: an opportunity for improvement. Infl amm Bowel Dis 2014; 20: 246-50
15. Huth KBE, Mack D. Focused education and vaccine access in clinic improve infl uenza vaccination rates in children with infl ammatory bowel disease. United European Gastroenterol J 2014; 2: A228
16. Wasan SK, Coukos JA, Farraye FA. Vaccinating the infl ammatory bowel disease patient: defi ciencies in gastroenterologists knowledge. Infl amm Bowel Dis 2011; 17: 2536-40
17. Parker S, Chambers White L, Spangler C et al. A quality improvement project signifi cantly increased the vaccination rate for immunosuppressed patients with IBD. Infl amm Bowel Dis 2013; 19: 1809-14
18. Tremaine WJ, Sandborn WJ, Loft us EV et al. A prospective cohort study of practice guidelines in infl ammatory bowel disease. Am J Gastroenterol 2001; 96: 2401-6